Baseline characteristics

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin · Source last updated 2016-07-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      118

   units

   Participants

groups

1. description

   All patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase. Patients included patients with pancreatic neuroendocrine tumors (PNETs), pituitary NETs (PiNETs), Ectopic ACTH-secreting tumor (EAS) \& Nelson's syndrome.

   id

   BG000

   title

   Pasireotide LAR 60mg

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            14.56

            value

            45.9

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   Years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            68

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            50

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

population Description

The full analysis set (FAS) consisted of all enrolled patients who received at least one dose of pasireotide LAR.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice